Literature DB >> 11176690

Diltiazem-associated photodistributed hyperpigmentation: a review of 4 cases.

L Scherschun1, M W Lee, H W Lim.   

Abstract

BACKGROUND: Diltiazem hydrochloride is a widely used calcium channel blocking agent. While a few cases of diltiazem-associated photosensitivity have been reported, no cases of photodistributed hyperpigmentation are known. OBSERVATION: Four cases of photodistributed hyperpigmentation associated with the long-acting formulation of diltiazem hydrochloride (Cardizem CD) are presented. All patients were African American women, with a mean age of 62 years. The mean duration of diltiazem administration prior to the development of hyperpigmentation was 8 months. The hyperpigmentation was slate-gray and reticulated. Phototesting during diltiazem therapy revealed a decreased minimal erythema dose to UV-A in 1 patient. Histopathologic examination showed lichenoid dermatitis with prominent pigmentary incontinence. Electron microscopic examination of the tissue revealed multiple melanosome complexes. Discontinuation of diltiazem therapy resulted in the gradual resolution of the hyperpigmentation.
CONCLUSIONS: Long-term administration of diltiazem may be associated with characteristic reticulated, slate-gray hyperpigmentation on sun-exposed areas. Discontinuation of the therapy results in resolution of the eruption.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11176690

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  3 in total

Review 1.  Drug-induced photosensitivity: culprit drugs, management and prevention.

Authors:  Aaron M Drucker; Cheryl F Rosen
Journal:  Drug Saf       Date:  2011-10-01       Impact factor: 5.606

2.  Hyperpigmentation Induced by Combination Therapy With Telmisartan-Hydrochlorothiazide.

Authors:  Rosa Giménez-García
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-09-11       Impact factor: 3.738

3.  Diltiazem-associated Photodistributed Hyperpigmentation.

Authors:  Jacob D Siegel; Christine J Ko
Journal:  Yale J Biol Med       Date:  2020-03-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.